AstraZeneca PLC
camizestrant
HR-positive, HER2-negative advanced breast cancer
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on camizestrant for HR-positive, HER2-negative advanced breast cancer is expected Date TBD.
Primary source
· SEC 6-K
verified 12h ago
“On 22 May, the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of the camizestrant combination in this setting based on the results of the SERENA-6 Phase III trial.”